{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:39:47Z","timestamp":1786995587108,"version":"build-2736575974"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.pharmthera.2024.108758","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:00:07Z","timestamp":1732366807000},"page":"108758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Optimizing drug therapies in cardiac amyloidosis"],"prefix":"10.1016","volume":"265","author":[{"given":"Mohamed","family":"Younis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikechukwu","family":"Ogbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh K.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of Neurohormonal antagonism in cardiac Amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"European Journal of Internal Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108758_bb0020","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10741-021-10162-1","article-title":"Epidemiology and clinical manifestations of cardiac amyloidosis","volume":"27","author":"Bajwa","year":"2022","journal-title":"Heart Failure Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaccas.2019.08.009","article-title":"Light-Chain Cardiac Amyloidosis","volume":"1","author":"Barge-Caballero","year":"2019","journal-title":"JACC Case Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108758_bb0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108758_bb0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jchf.2020.01.011","article-title":"Percutaneous left axillary artery placement of intra-aortic balloon pump in advanced heart failure patients","volume":"8","author":"Bhimaraj","year":"2020","journal-title":"JACC Heart Failure"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World heart federation consensus on transthyretin Amyloidosis cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Global Heart"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108758_bb0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: An age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genetics in Medicine: Official Journal of the American College of Medical Genetics"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: Studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"Journal of Translational Medicine"},{"issue":"38","key":"10.1016\/j.pharmthera.2024.108758_bb0060","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"European Heart Journal"},{"issue":"24","key":"10.1016\/j.pharmthera.2024.108758_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between Neurohormonal blockade and survival in transthyretin cardiac Amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0070","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Advances"},{"issue":"suppl_1","key":"10.1016\/j.pharmthera.2024.108758_bb0075","first-page":"A18064","article-title":"Abstract 18064: Outcome of implantable defibrillator therapy in patients with cardiac Amyloidosis","volume":"136","author":"Chuzi","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108758_bb0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/CIRCULATIONAHA.120.046680","article-title":"Complexities and pitfalls in cardiac Amyloidosis","volume":"142","author":"Cuddy","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0085","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in transthyretin cardiomyopathy clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin Amyloidosis","volume":"379","author":"David","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1016\/j.pharmthera.2024.108758_bb0100","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108758_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"American Journal of Hematology"},{"issue":"18","key":"10.1016\/j.pharmthera.2024.108758_bb0110","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary results from the phase 3 Tourmaline-AL1 Trial of Ixazomib-dexamethasone versus Physician\u2019s choice of therapy in patients (pts) with relapsed\/refractory primary systemic AL Amyloidosis (RRAL)","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108758_bb0120","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage Thrombus in patients with transthyretin Amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC. Clinical Electrophysiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108758_bb0125","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac Amyloidosis: Predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC. Clinical Electrophysiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108758_bb0130","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108758_bb0135","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac Amyloidosis: Part 1 of 2\u2014Evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circulation. Cardiovascular Imaging"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108758_bb0140","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nature Structural & Molecular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108758_bb0145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac Amyloidosis","volume":"73","author":"El Am Edward","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2021","journal-title":"Circulation. Heart Failure"},{"issue":"Suppl B","key":"10.1016\/j.pharmthera.2024.108758_bb0155","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","article-title":"Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis","volume":"25","author":"Emdin","year":"2023","journal-title":"European Heart Journal Supplements: Journal of the European Society of Cardiology"},{"issue":"13","key":"10.1016\/j.pharmthera.2024.108758_bb0160","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.pharmthera.2024.108758_bb0165","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","article-title":"Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity","volume":"583","author":"Ferreira","year":"2009","journal-title":"FEBS Letters"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108758_bb0170","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMcp074189","article-title":"Clinical practice. Neurogenic orthostatic hypotension","volume":"358","author":"Freeman","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108758_bb0180","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","article-title":"A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model","volume":"41","author":"George","year":"2020","journal-title":"European Heart Journal"},{"issue":"Supplement_1","key":"10.1016\/j.pharmthera.2024.108758_bb0185","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of Care in Patients with light chain (AL) Amyloidosis suggest survival benefit for Mayo stage IV patients","volume":"134","author":"Gertz","year":"2019","journal-title":"Blood"},{"issue":"13 Pt 1","key":"10.1016\/j.pharmthera.2024.108758_bb0190","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"The American Journal of Cardiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108758_bb0195","first-page":"351","article-title":"Management of Arrhythmias in cardiac Amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC: Clinical Electrophysiology"},{"issue":"30","key":"10.1016\/j.pharmthera.2024.108758_bb0200","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108758_bb0205","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of Acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0215","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.healun.2013.09.004","article-title":"Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis","volume":"33","author":"Gray Gilstrap","year":"2014","journal-title":"The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0220","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.healun.2021.10.007","article-title":"Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies","volume":"41","author":"Griffin","year":"2022","journal-title":"The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108758_bb0225","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR Amyloidosis: Current and emerging management strategies: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC. CardioOncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108758_bb0230","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006848","article-title":"Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with Midodrine in patients with orthostatic hypotension","volume":"6","author":"Grijalva","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108758_bb0235","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac Amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108758_bb0240","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: Results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.pharmthera.2024.108758_bb0245","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: Executive summary: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0250","doi-asserted-by":"crossref","first-page":"41515","DOI":"10.1038\/srep41515","article-title":"Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains","volume":"7","author":"Hora","year":"2017","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0255","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: A review","volume":"27","author":"Ibrahim","year":"2022","journal-title":"Heart Failure Reviews"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108758_bb0260","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-na\u00efve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108758_bb0265","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0270","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) Amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108758_bb0275","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.jcmg.2020.06.016","article-title":"Teaching an old dog new tricks: Using cardiac CT for comprehensive imaging","volume":"13","author":"Kalra","year":"2020","journal-title":"JACC. Cardiovascular Imaging"},{"issue":"28","key":"10.1016\/j.pharmthera.2024.108758_bb0280","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and dexamethasone for light-chain Amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0285","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2019-126524","article-title":"Daratumumab monotherapy in previously untreated high-risk patients with stage 3B light chain (AL) Amyloidosis: A phase II multicenter study by European myeloma Network (EMN)","volume":"134","author":"Kastritis","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0290","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108758_bb0295","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.pharmthera.2024.108758_bb0300","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: First approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"9_Supplement_1","key":"10.1016\/j.pharmthera.2024.108758_bb0305","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0735-1097(19)31444-5","article-title":"Does an implantable defibrillator alter outcomes in patients with cardiac amyloidosis?","volume":"73","author":"Kim","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary Care for the Patient with Cardiac Amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108758_bb0315","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13663","article-title":"Mechanical circulatory support for cardiac amyloidosis","volume":"33","author":"Kittleson","year":"2019","journal-title":"Clinical Transplantation"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0320","doi-asserted-by":"crossref","DOI":"10.21542\/gcsp.2023.4","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Global Cardiology Science & Practice"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108758_bb0325","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108758_bb0330","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: An observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clinical Research in Cardiology: Official Journal of the German Cardiac Society"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108758_bb0335","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108758_bb0340","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s10741-021-10209-3","article-title":"State-of-the-art review on management of end-stage heart failure in amyloidosis: Transplant and beyond","volume":"27","author":"Kumar","year":"2022","journal-title":"Heart Failure Reviews"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108758_bb0345","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: Multiple myeloma, version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108758_bb0350","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain Amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","article-title":"Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: A multicentric retrospective study and review of the literature","volume":"27","author":"Lecumberri","year":"2020","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"issue":"13","key":"10.1016\/j.pharmthera.2024.108758_bb0360","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain Amyloidosis: Results of a phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0365","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0672","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"Journal of Biomedical Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0370","doi-asserted-by":"crossref","first-page":"181","DOI":"10.31083\/j.rcm.2020.02.65","article-title":"Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction","volume":"21","author":"Madan","year":"2020","journal-title":"Reviews in Cardiovascular Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108758_bb0375","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and Management of Cardiac Amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.pharmthera.2024.108758_bb0380","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac Amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108758_bb0385","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108758_bb0395","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0142-x","article-title":"Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis","volume":"99","author":"Mereles","year":"2010","journal-title":"Clinical Research in Cardiology: Official Journal of the German Cardiac Society"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2024.108758_bb0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8073","article-title":"The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction","volume":"34","author":"Merlini","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0405","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nature Communications"},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108758_bb0410","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0415","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: Contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"issue":"24","key":"10.1016\/j.pharmthera.2024.108758_bb0420","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.3390\/ijms232416145","article-title":"Oral therapy for the treatment of transthyretin-related amyloid cardiomyopathy","volume":"23","author":"Nuvolone","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0425","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study","volume":"19 Suppl 1","author":"Obici","year":"2012","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0430","author":"Palladini"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0435","author":"Palladini"},{"issue":"19","key":"10.1016\/j.pharmthera.2024.108758_bb0440","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108758_bb0445","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108758_bb0450","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: Long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108758_bb0455","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: A matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0460","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Annals of Hematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0465","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108758_bb0470","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108758_bb0475","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14656566.2019.1574746","article-title":"Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases","volume":"20","author":"P\u00e9rez-Lloret","year":"2019","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"24","key":"10.1016\/j.pharmthera.2024.108758_bb0480","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"24","key":"10.1016\/j.pharmthera.2024.108758_bb0485","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"European Heart Journal"},{"issue":"422","key":"10.1016\/j.pharmthera.2024.108758_bb0490","doi-asserted-by":"crossref","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0495","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","volume":"23","author":"Rosenblum","year":"2021","journal-title":"European Journal of Heart Failure"},{"issue":"18","key":"10.1016\/j.pharmthera.2024.108758_bb0500","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108758_bb0505","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108758_bb0510","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1074\/jbc.RA118.005257","article-title":"A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils","volume":"294","author":"Saelices","year":"2019","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0515","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720987075","article-title":"Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed\/refractory multiple myeloma","volume":"12","author":"Sanchez","year":"2021","journal-title":"Therapeutic Advances in Hematology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0520","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: Clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"issue":"18","key":"10.1016\/j.pharmthera.2024.108758_bb0525","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: Results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0530","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"issue":"34","key":"10.1016\/j.pharmthera.2024.108758_bb0535","doi-asserted-by":"crossref","first-page":"23704","DOI":"10.18632\/oncotarget.25281","article-title":"Efficacy and safety of carfilzomib in relapsed and\/or refractory multiple myeloma: Systematic review and meta-analysis of 14 trials","volume":"9","author":"Shah","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0540","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.121.055953","article-title":"Doxycycline combined with Bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain Amyloidosis: A multicenter randomized controlled Trial","volume":"145","author":"Shen","year":"2022","journal-title":"Circulation"},{"issue":"11_Supplement_1","key":"10.1016\/j.pharmthera.2024.108758_bb0545","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1016\/S0735-1097(20)34206-6","article-title":"Study design and rationale of helios-b: A phase 3 study to evaluate the clinical efficacy and safety of vutrisiran in patients with attr amyloidosis with cardiomyopathy","volume":"75","author":"Shilling","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0550","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13506129.2021.2000388","article-title":"Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: The Boston University Amyloidosis center experience","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0555","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108758_bb0560","first-page":"795","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac Amyloidosis. JACC","volume":"9","author":"Sperry","year":"2021","journal-title":"Heart Failure"},{"issue":"8_Supplement","key":"10.1016\/j.pharmthera.2024.108758_bb0565","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0735-1097(23)00780-5","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in attr-act","volume":"81","author":"Sperry","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108758_bb0570","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: A 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0575","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac Amyloidosis\u2014A clinical feasibility study. Journal of","volume":"13","author":"Steinhardt","year":"2024","journal-title":"Clinical Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0580","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14797\/mdcvj.1050","article-title":"Cardiac Amyloidosis treatment","volume":"18","author":"Stern","year":"2022","journal-title":"Methodist DeBakey Cardiovascular Journal"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108758_bb0585","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0590","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Annals of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108758_bb0595","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac Amyloidosis: JACC review topic of the week","volume":"74","author":"Ternacle","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0600","doi-asserted-by":"crossref","first-page":"1154594","DOI":"10.3389\/fcvm.2023.1154594","article-title":"Treating amyloid transthyretin cardiomyopathy: Lessons learned from clinical trials","volume":"10","author":"Tomasoni","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108758_bb0605","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.currproblcancer.2016.09.006","article-title":"Palliative care and symptom management in amyloidosis: A review","volume":"40","author":"Tsukanov","year":"2016","journal-title":"Current Problems in Cancer"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0610","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139323","article-title":"Cael-101 is well-tolerated in AL Amyloidosis patients receiving concomitant cyclophosphamide-Bortezomib-dexamethasone (CyborD): A phase 2 dose-finding study (NCT04304144)","volume":"136","author":"Valent","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0615","article-title":"Prothena announces discontinuation of AL amyloidosis drug NEOD001","author":"Vallejo","year":"2018","journal-title":"Myeloma Patients Europe."},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0620","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0625","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-019-0266-9","article-title":"Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: A pooled analysis","volume":"10","author":"Warsame","year":"2020","journal-title":"Blood Cancer Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0630","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: A systematic review and Meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108758_bb0635","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","article-title":"Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: An open-label phase 2 study and an adjunctive immuno-PET imaging study","volume":"22","author":"Wechalekar","year":"2022","journal-title":"BMC Cardiovascular Disorders"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2024.108758_bb0640","doi-asserted-by":"crossref","first-page":"e990776f","DOI":"10.1097\/01.HS9.0000975360.99077.6f","article-title":"PB2150: Cardiac amyloid reaching for extended survival (cares) trials: 2 placebo-controlled, double-blind, randomized, phase 3 trials assessing CAEL-101 in patients with Mayo stages IIIA\/IIIB al amyloidosis","volume":"7","author":"Wechalekar","year":"2023","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108758_bb0645","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","article-title":"Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis","volume":"109","author":"Wechalekar","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0650","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108758_bb0655","first-page":"516","article-title":"Cardiac transplantation and mechanical circulatory support in Amyloidosis","volume":"3","author":"Witteles","year":"2021","journal-title":"JACC: CardioOncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108758_bb0671","first-page":"709","article-title":"Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC: Heart Failure"},{"issue":"sup1","key":"10.1016\/j.pharmthera.2024.108758_bb0660","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13506129.2019.1593133","article-title":"The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition","volume":"26","author":"Wixner","year":"2019","journal-title":"Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis"},{"key":"10.1016\/j.pharmthera.2024.108758_bb0665","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.2147\/CMAR.S218979","article-title":"Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Management and Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108758_bb0670","first-page":"438","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin Amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC: Basic to Translational Science"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T04:29:54Z","timestamp":1733891394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824001785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":136,"alternative-id":["S0163725824001785"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108758","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing drug therapies in cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108758"}}